Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Ovarian Neoplasms 675Breast Neoplasms 265Uterine Cervical Neoplasms 240Carcinoma, Non-Small-Cell Lung 218Endometrial Neoplasms 201Fallopian Tube Neoplasms 187Carcinoma, Ovarian Epithelial 175Colorectal Neoplasms 164Stomach Neoplasms 152Pancreatic Neoplasms 144Neoplasms 143Melanoma 118Lung Neoplasms 112Carcinoma, Renal Cell 111Triple Negative Breast Neoplasms 108Prostatic Neoplasms 108Squamous Cell Carcinoma of Head and Neck 98Neoplasm Metastasis 96Esophageal Neoplasms 90Urinary Bladder Neoplasms 85Head and Neck Neoplasms 83Sarcoma 69Small Cell Lung Carcinoma 64Carcinoma, Hepatocellular 64Colonic Neoplasms 56Carcinoma, Transitional Cell 49Kidney Neoplasms 41Testicular Neoplasms 38Peritoneal Neoplasms 37Anus Neoplasms 34

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cervical Adenocarcinoma × Gynecologic × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡